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Abstract
Background: The signal transducer and activator of transcription-3 (STAT-3) can facilitate cancer progression and
metastasis by being constitutively active via various signaling. Abundant evidence has indicated that STAT-3 may be
a promising molecular target for cancer treatment.
Methods: In this study, a dual-luciferase assay-based screening of 537 compounds for STAT-3 inhibitors of
hepatocellular carcinoma (HCC) cells was conducted, leading to the identification of genipin. Effects of genipin on HCC
were assessed in a patient-derived xenograft nude mice model. Western blotting assay, chromatin
immunoprecipitation (ChIP) assay, molecular docking study, tube formation assay, three-dimensional top culture assay,
histological examination, and immunofluorescence were utilized to evaluate the regulatory signaling pathway.
Results: Our research demonstrated that genipin suppresses STAT-3 phosphorylation and nuclear translocation, which
may be attributed to the binding capacity of this compound to the Src homology-2 (SH2) domain of STAT-3. In
addition, the therapeutic effects of genipin in a patient-derived HCC xenograft nude mice model were also
demonstrated.
Conclusions: In conclusion, genipin showed therapeutic potential for HCC treatment by interacting with the SH2-
STAT-3 domain and suppressing the activity of STAT-3. In the future, further research is planned to explore the
potential role of genipin in combination with chemotherapy or radiotherapy for HCC.
Background
The signal transducer and activator of transcription-3
(STAT-3) was originally identified as a critical mediator
of the IL-6-type cytokine signal pathway and described
as an acute phase response factor (APRF) [1, 2], which
can operate as a transcription factor of various cytokines,
interferons, hormones, and growth factors [3]. After
dimerization, STAT-3 can transfer to the nucleus and
act as a transcription activator. Phosphorylation of
tyrosine 705 residue induced by epidermal growth factor
(EGF) or interleukins can activate STAT-3 in cells [4].
STAT-3 can facilitate cancer progression and metastasis
by being constitutively active via various signaling, as
previously described [5, 6]. Abundant evidence indicates
that STAT-3 may be a promising molecular target for
cancer treatment. Inhibiting of STAT-3 activity can be
divided into two categories: regulating upstream genes
of STAT-3 or directly binding to STAT-3 and suppress-
ing its activity [7]. Although the direct targeting of
STAT-3 is extremely difficult, novel targeting agents
continuously emerge. For example, Bai et al. recently
found a highly selective small-molecule degrader of
STAT-3, i.e., SD-36, which could suppress lymphoma
cell growth and inhibit tumor progression in a mice
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model. In addition, several natural products, such as alan-
tolactone and osthole, can suppress the phosphorylation
and activation of STAT-3 as well as inhibit tumor progres-
sion in breast cancer by directly binding with the SH2 do-
main of STAT-3 [8, 9]. However, none of these candidate
agents have been assessed for their binding affinity to
STAT-3. Their selectivity with STAT-3 and other STAT
family proteins still needs further exploration.
Hepatocellular carcinoma (HCC) is a highly fatal ma-
lignant disease that is the third leading cause of cancer-
related deaths in developing countries [10]. Most HCC
patients are diagnosed at an advanced stage, and there-
fore these patients have few chances for radical therapy.
Although major progress in HCC treatment has been
achieved in recent years, HCC patients still have a poor
prognosis, with high rates of metastasis and post-
operative recurrence [11]. Thus, further exploring the
underlying molecular mechanisms of HCC and develop-
ing highly effective therapies for HCC are urgently
needed. Persistent activation of STAT-3 has been found
in the majority of HCC patient tissues instead of para-
carcinoma tissue and has been closely associated with
poor prognosis [12]. Studies have increasingly shown
that STAT-3 plays critical roles in HCC growth and me-
tastasis. Therefore, STAT-3 may be a promising thera-
peutic target in HCC treatment. Clinical studies have
explored the potential benefits of STAT-3-targeted
agents used either alone or in combination with chemo-
therapy in HCC patients. Some of these agents have re-
vealed a promising clinical efficacy and safety profile in
clinical trials [13].
In this study, a dual-luciferase assay-based screening
of 537 compounds for STAT-3 inhibitors was con-
ducted, leading to the identification of genipin. Further
research demonstrated that genipin suppresses STAT-3
phosphorylation and nuclear translocation, which may
be attributed to the binding capacity of this compound
to the SH2 domain of STAT-3. Furthermore, the thera-
peutic effects of genipin were also evaluated in a patient-
derived HCC xenograft mice model.
Materials and methods
Cell lines
MHCC97L, HepG2, and LO2 cells were obtained from
the American Type Culture Collection (Manassas, VA).
The cells were cultured in RPMI 1640 medium contain-
ing 10% FBS at 37 °C in a humidified atmosphere con-
taining 4% CO2. Media were supplemented with
antibiotics including 150 μg/ml of streptomycin and 50
U/ml of penicillin.
Luciferase reporter assay
The luciferase reporter system was applied using the
pGMSTAT-3-Luc plasmid for detecting the activation of
STAT-3. The plasmid was purchased from Genomedi-
tech (#GM-021003, Shanghai, PRC) and transfected into
cells following the instructions from a previous study
[14]. Before plasmid transfection, MHCC97L cells were
cultured in a 12-well plate for 12 h. Co-transfection of
pRL-SV40 (Renilla luciferase) and pGMSTAT-3-Luc was
conducted by Lipofectamine 3000 (Thermo Scientific,
USA) in MHCC97L cells. One day after transfection,
MHCC97L cells were exposed to the test chemicals from
our internal chemicals library, which were provided by
Prof. Ma of the Xi’an Jiao Tong University Medical
School for 12 h [15]. The exposure time and concentra-
tion of the chemicals library were referred to previous
studies [15]. Geniposide was purchased from Sigma Co.
Ltd. (purity> 99% by HPLC). The luciferase signal was
analyzed using the dual-luciferase reporter systems as
previously described [16]. The activation of STAT-3 reg-
ulated by candidate agents was analyzed by the propor-
tion between the value of Renilla and firefly luciferase
activity.
Immunoblotting
Immunoblotting assay was conducted as previously de-
scribed [17]. The nuclear and cytosol proteins were ex-
tracted using the Nuclear Protein Extraction kit
(Fermentas, USA). The related primary antibodies and
secondary antibodies were purchased from Abcam
(Cambridge, USA). The following primary antibodies
were used for immunoblots at the appropriate dilutions:
p-stat3-Tyr705 (1:1000), p-stat3-Ser727 (1:1000), stat3
(1:1000), GAPDH (1:5000), Surviving (1:500), Mcl-1 (1:
1000), Bcl-2 (1:1000), VEGF (1:500), MMP2 (1:1000),
Socs3 (1:500), PARP (1:500), Cleavage PARP (1:500), N-
cadherin (1:1000), E-cadherin (1:1000), Vinmentin (1:
1000), and Fibronection (1:500).
Real-time PCR
Total RNA was isolated using TRIzol (Sigma, USA) fol-
lowing the instructions of the manufacturer. The puri-
fied RNA was then reverse-transcribed to cDNA with
the Invitrogen SuperScript IV kit. Real-time PCR experi-
ments were conducted using the SYBR Green PCR Kit
(QIAGEN, China) and reactions were performed for 40
cycles in standard mode using the Bio-Rad CFX96 PCR
System. The primers used in this study are shown in
Supplementary Table 3. Each reaction was performed in
triplicate.
Cell viability assay
Cell viability was examined by using the 3-(4,5-dimethyl-
thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophe-
nyl)-2H-tetrazolium (MTS) assay as previously described
[3]. Absorbance was recorded at 490 nm using a Bio-rad
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PR-4100 microplate reader (Hercules, USA). Each reac-
tion was performed in triplicate.
Immunofluorescent staining
Immunofluorescence staining was performed referred to
previous studies [18]. Briefly, after fixation with 4% para-
formaldehyde, cells were blocked and hybridized with
the indicated primary antibodies for 12 h. Next, fluores-
cein isothiocyanate (FITC)-conjugated secondary anti-
bodies were added and incubated for 2 h; 4′,6-
diamidino-2-phenylindole (DAPI) was used for nuclear
staining. The fluorescent expressions of the target
marker and nucleus were visualized by a confocal micro-
scope (Olympus, Japan).
Electrophoretic mobility shift assay
Electrophoretic mobility shift assay (EMSA) was con-
ducted to evaluate the DNA-binding activity of STAT-3 in
genipin-treated HCC cells. In brief, following transfection
of HCC cells for 72 h, nuclear proteins from each sample
were extracted with a Nuclear Extraction kit (Sigma, USA)
and subjected to EMSA following the manufacturer’s
standard protocol using the LightShift® Chemiluminescent
EMSA kit (Thermo Fisher Scientific, USA). The STAT-3
target probe was synthesized with a 3′-biotin modification
(Invitrogen, USA) and the sequence was 5′-ACG AAC
CAT TACGCTCGA CAG CCG-3′, in which the binding
region is underlined. EMSA was conducted with STAT-3
EMSA Kit (Thermo Fisher Scientific, USA) following the
manufacturer’s instructions. STAT-3 oligonucleotides




HCC cells were added into formaldehyde for immobiliz-
ing the protein-DNA complex for chromatin immuno-
precipitation (ChIP) assay. Then, cell lysis solution was
added. DNA fragments were broken by ultrasound. The
related antibodies and beads were added to precipitate
the protein-DNA complex. The protein-DNA complex
was immunoprecipitated with STAT-3 antibody. Protein
A/G agarose beads were applied to incubate with the im-
munoprecipitate. Next, the samples were washed by PBS
and the chromatin-protein complex was reversed.
Phenol-chloroform was used to purify the DNA. Then,
DNA sequences were validated by qPCR assay. The
primers used in ChIP assay were specific for STAT3-
binding sites in the promoters of VEGF, SOCS3, and
BCL-2.
Molecular docking study
The three-dimensional (3D) structures of STAT-3 were
obtained from the RSCB Protein Data Bank (http://www.
pdb.org/) (PDB code: 6NJS) and prepared with Sybyl-X
2.0 (Tripos, St. Louis, MO, USA) for the docking studies
[19]. An energy-minimized 3D structure of Genipin
(PubChem: 442424) was optimized from NCBI-
PubChem (https://pubchem.ncbi.nlm.nih.gov/). The
elaborate docking method and reliability validated assay
were recorded in the protocol of the Surflex-Dock mod-
ule of Sybyl-X [20].
Surface-plasmon-resonance assay
Surface-plasmon-resonance (SPR) assay was applied to
further validate the binding affinity of genipin with
STAT-3-SH2 protein. The STAT-3-SH2 peptide se-
quence, FISKERERAILSTKPPGTFLLRFSESSK, was pro-
vided by Peptide 2.0 (Fairfax, VA) at > 95% purity. SPR
binding assay was performed with Biocore T300 biosen-
sor systems (General Electric, USA) as previously de-
scribed [21]. All the SPR-based materials were obtained
from General Electric Co. The related target proteins
were acquired from R&D systems (Minneapolis, USA).
Biocore trace was baseline-subtracted and the signals
were presented in sensorgrams and determined in RU.
Empirically, in the BIOcore technology, 2 ng of analyte
bound at the surface gave a response of 1× 103 RU.
Equilibrium constants (KD) were calculated with the “af-
finity” model in Biocore T300 evaluation software ver-
sion 3.2.
Tube formation assay
HCC cells were plated in a six-well plate to 95% conflu-
ence after 36 h, and then the cells were washed with PBS
and the medium substituted by serum-free medium with
different concentrations of genipin (0, 10, and 20 μM).
Conditioned media were collected after centrifugation at
1200 rpm for 10 min. A total of 2 × 104 HUVECs were
seeded into each well of a 12-well plate coated with
200 μL of Matrigel (Sigma, USA), and cultured for 8 h in
conditioned medium. Images were captured by an
Olympus CKX41 inverted microscope (magnification
100×; Olympus Corp., USA), and analyzed for the extent
of tube formation by measuring the tube length and
counting the number of tube nodes using ImageJ soft-
wareEach reaction was performed in triplicate.
Immunohistochemistry assay
Immunohistochemical staining was performed according
to previous studies [22]. Antibodies for p-STAT-3 (dilu-
tion 1:200) and CD31 (dilution 1:200) were provided by
Invitrogen (Carlsbad, CA, USA). Immunohistochemistry
assay was performed in an automated system using the
Ventana® BenchMark Ultra following the manufacturer’s
protocols. The immunohistochemistry slides were exam-
ined by three independent researchers. Positivity for p-
STAT-3 and CD31 was defined as unequivocally nuclear
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and cytoplasmic staining of at least 75% of the cancer
cells.
3D top culture assay
Growth-factor-reduced Matrigel was thawed at 4 °C for
12 h. Matrigel solution (60 μL/well) was added into 24-
well plates at 35 °C for 20 min. A total of 2 × 105
MHCC97L cells were re-suspended in 150 μL of serum-
free medium and cultured on solidified Matrigel. At 15
min post-cell-attachment, 150 μL of serum-free media
with 15% Matrigel and indicated concentrations of geni-
pin were added on top of the plated culture. All experi-
ments were repeated by three independent researchers.
Animal studies
For details of the construction of HCC xenograft nude
mice models, BALB/C mice (4 weeks old, female) were
orthotopically implanted with 2 × 105 MHCC97L cells,
the reader is referred to our previous studies [19]. The
mice were anesthetized by intramuscular injection of 0.2
ml of a solution of 25 mg/kg ketamine and 15 mg/kg
xylazine. Two weeks later, the BALB/C mice were ran-
domly divided into a DMSO group (n = 8), 25-mg/kg/d
genipin treatment group (n = 8), and 50-mg/kg/d genipin
treatment group (n = 8) by i.p. injection. Thirty-five days
after treatment, the mice were sacrificed and dissected.
The liver tumor weight and lung metastasis nodules
were measured by three independent researchers. All
animal studies were approved and under the strict
supervision of the University of Kansas Committee of
Experimental Animal Ethics (Approval No.
CF201900239).
For the patient-derived xenograft (PDX) model, HCC
cells were collected for constructing a xenograft model
as previously described [10]. Seven surgical liver samples
were obtained from HCC patients in the Department of
Hepatobiliary Surgery of the First Affiliated Hospital of
Guangzhou University of Chinese Medicine (Supple-
mentary Table 1). The tumor tissue was incised into
small pieces (0.3 cm3). Ethanol (75%) was used for surgi-
cal disinfection. For anesthesia of the mice, 0.6% lido-
caine was applied. For establishing the F1 generation,
one piece of the human HCC tissue was sent into the
subcutaneous area. When the tumor volume grew to 1
cm3, the tumor was dissected into two pieces. One piece
of tumor was fixed in 4% formaldehyde solution and the
other was further incised into small pieces (0.3 cm3).
Eight BALB/C mice were transplanted with tumor tissue
as described above (F2 generation). The PDX mice
model of F3 generation was also conducted as described
above. Then, the mice were randomly divided into a
DMSO group (n = 8), 25-mg/kg/d genipin treatment
group (n = 8), and 50-mg/kg/day genipin treatment
group (n = 8) by i.p. injection. Tumor volumes were
measured at the indicated time points. All procedures
and protocols were approved by the Ethical Committee
of the First Affiliated Hospital of Guangzhou University
of Chinese Medicine.
Statistical analysis
All data were presented as mean ± standard deviation
(SD) of three independent experiments. The statistical
analyses were evaluated by GraphPad Prism using Stu-
dent’s t-test for comparing two means. Analysis of vari-
ance (ANOVA) followed by Tukey’s post hoc test was
applied for the statistical analysis when more than two
means were compared. P values of less than 0.05 were
considered statistically significant.
Results
Genipin can inhibit the phosphorylation of STAT-3 (Tyr)
and decrease the expression of STAT-3 target gene in
HCC cells
As a transcription factor, STAT-3 can regulate cell pro-
liferation and angiogenesis through modulation of its
downstream target genes, such as Bcl-2, VEGF, and
SOCS-3 [23]. To screen novel STAT-3 inhibitory agents,
the STAT-3 luciferase reporter system was applied to
screen target agents from our internal chemicals library
(Fig. 1a, upper panel). After screening 537 compounds,
genipin was eventually identified as a novel natural agent
for inhibiting the STAT-3 signal pathway. Genipin ex-
hibited significant STAT-3 suppressive activity in
MHCC97L and HepG2 cells (Fig. 1a, lower panel).
While phosphorylated Y705 has been widely acknowl-
edged to be essential for STAT-3’s transcriptional activ-
ity, the function of phosphorylated S727 is still
controversial, as this modification has been reported to
have both up- and down-regulatory effects on STAT3’s
transcriptional activity. Thus, for validating the STAT-3
suppressive effects, p-STAT-3 (Y705) and p-STAT-3
(S727) expression were examined by western blot after
genipin treatment. Our results showed that genipin
(20 μM) remarkably inhibited the activation of pSTAT-3
(Y705), but failed to affect the protein expression of
STAT-3 and p-STAT-3 (S727) (Fig. 1b). In addition, one
of genipin’s relative compounds, geniposide, was chosen
as a control to confirm the specificity effect of genipin
on STAT-3 inhibition. However, our results showed that
geniposide has no effect on STAT-3 inhibition in HCC
cells (Figs. 1a and b). Cytoplasmic STAT-3 exported to
the nucleus is a critical step for regulating its down-
stream gene expression. Both immunofluorescent stain-
ing and western blotting results confirmed that genipin
inhibited nuclear translocation of STAT-3 after being
stimulated by Interleukin-6 (IL-6) (Fig. 1c). Furthermore,
STAT-3 DNA-binding ability was inhibited by genipin
treatment according to the electrophoretic mobility shift
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assay results (Fig. 1d). Protein tyrosine phosphatases
(PTPases) are a group of enzymes that are able to elim-
inate the DNA binding of STAT-3 [24]; thus, it was our
intention to explore whether genipin could inhibit
STAT-3 by PTPases in HCC. PTEN, SHP1, and SHP2
are key regulatory PTPases in STAT-3 signal transduc-
tion pathways [25]; however, the protein expression of
these PTPases has no obvious changes after genipin
treatment (Supplementary Fig. 1a). In addition, to fur-
ther confirm whether genipin inhibits STAT-3 specific-
ally, the activities of STAT-5, STAT-1, STAT-2, mTOR,
and MAPK signal pathways were also evaluated by west-
ern blotting. Our results indicated that genipin failed to
affect the phosphorylation of STAT-5, STAT-1, and
STAT-2 as well as the expression of the related proteins
in mTOR and MAPK signal pathways (Supplementary
Figs. 1b and c). Up to now, it could be concluded that
genipin suppressed STAT-3 phosphorylation and nu-
clear translocation as well as inhibited its DNA-binding
ability. STAT-3 dimers exported to the nucleus can acti-
vate the promoter of STAT-3 target genes and up-
regulate the protein expression of these tumor-related
genes, such as Survivin, Bcl-2, MMPs, SOCS3, and
VEGF [18]. Western blot assay results further confirmed
that genipin treatment decreased the expression of
STAT-3 target genes in HCC cells (Fig. 1e). In addition,
Fig. 1 Genipin suppresses STAT-3 activity in HCC. (a) HCC cells were treated with genipin or geniposide for 24 h before transfection with plasmid
containing the luciferase reporter gene. Relative luciferase activity was detected using dual-luciferase reporter systems. (b) Liver cancer cells were
treated with genipin or geniposide for 24 h, and western blot was performed to detect the protein expressions of STAT-3, p-STAT-3 (Y705), and p-
STAT-3 (S727). (c) MHCC97L cells were seeded in coverslips coated with gelatin, and then genipin (0–20 μM) was added into each sample for 12 h
and co-cultured with or without 10-ng/μl IL-6 for 20 min. STAT-3 expression and location was examined by immunofluorescent staining. Cell
nuclei were detected by DAPI stanning (left). MHCC97L cells were seeded in coverslips coated with gelatin, and then cells were treated with
genipin for 12 h and co-cultured with or without 10-ng/μl IL-6 for 20 min. Cytoplasmic and nuclear STAT-3 levels were detected by western
blotting assay (right). (d) MHCC97L cells were exposed to genipin for 24 h. STAT-3 DNA-binding activity was analyzed by EMSA assay. (e)
MHCC97L cells were exposed to genipin for 24 h. The protein expression of STAT-3 target genes were examined by western blot assay. (f)
MHCC97L cells were exposed to genipin for 24 h. Binding ability of STAT-3 with its target genes was analyzed by ChIP assay. Data presented as
mean ± SD. *P < 0.05 and **P < 0.01
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chromatin immunoprecipitation assay indicated that
genipin inhibited the binding affinity of STAT-3 with
Bcl-2, SOCS3, and VEGF (Fig. 1f). In summary, the
above data revealed that genipin could inhibit STAT-3
phosphorylation (Y705) and suppress its target gene ex-
pression in liver cancer.
Genipin binds to SH2 domain in STAT-3
Next, whether genipin could directly interact with
STAT-3 by in silico assay was explored. As shown in
Fig. 2a, genipin was docked nicely into the SH2 domain
of STAT-3 (PDB Id: 1GB1). PHE716, LYS626, GLN635,
SER636, GLU638, ARG609, LYS591, VAL637, PRO639,
and TRP623 of STAT-3 formed strong interactions with
genipin. To further confirm whether genipin can directly
bind to the STAT-3-SH2 domain, GST-tagged STAT-3-
SH2 domain (42 KD; see below) was purified from E.
coli (Fig. 2b). Then, SPR assay was performed to deter-
mine the binding affinity between genipin and STAT-3-
SH2. SPR analysis results indicated that STAT-3-SH2
bound to genipin with a relatively low dissociation con-
stant (KD) value (KD = 2.3 μM) (Fig. 2c). The activation
of STAT-3 required phosphorylation on tyrosine and
forming a dimer via phosphotyrosine/SH2 domain inter-
action [26]. Our results showed that genipin distinctly
suppressed the interaction between purified STAT-3-
SH2 and STAT-3 by GST pull-down assay (Fig. 2d).
Next, FLAG-tagged and HA-tagged STAT-3 vectors
were constructed and transfected into MHCC97L cells
for validating whether genipin inhibits the dimerization
of STAT-3. Our results suggested that HA-STAT-3 co-
immunoprecipitated with FLAG-STAT-3 in MHCC97L
cells and genipin blocked the interplay dose-dependently
(Fig. 2e). In addition, genipin also inhibited STAT-1:
STAT-3 heterodimer formation (Supplementary Fig. 2a).
These results indicated that genipin might directly bind
to the STAT-3-SH2 domain and inhibit the dimerization
of STAT-3 or STAT-1:STAT-3. EGFR can also bind to
the STAT-3-SH2 domain and activate STAT-3 [27].
GST pull-down results indicated that purified STAT-3-
SH2 interplayed with EGFR and genipin exposure
(20 μM) suppressed the complex formation (Fig. 2f).
Then, whether genipin could induce the dissociation of
the EGFR-STAT-3 complex was further explored. It was
found that treatment with EGF can increase the binding
ability of STAT-3 to EGFR in HCC cells, while treat-
ment with genipin significantly suppressed these interac-
tions (Fig. 2g). These results demonstrated that genipin
directly bonded with the STAT-3-SH2 domain.
Genipin inhibits HCC cell proliferation and angiogenesis
in vitro
The above results clearly demonstrated that genipin can
inhibit STAT-3 activation. To evaluate the anti-cancer
effect of genipin, its potential suppressive effect on HCC
cell proliferation was examined by MTS assay. To our
surprise, genipin remarkably inhibited HepG2 and
MHCC97L cell viability dose-dependently. However, no
significant inhibition effect on normal liver cells (LO2)
was observed in our study (Fig. 3a). Western blotting re-
sults showed that the phospho-STAT-3 (Tyr-705) level
was decreased after genipin treatment in HCC cells, but
remained unchanged in normal liver cells (LO2) (Sup-
plementary Fig. 3a). Next, whether STAT-3 inhibition is
related to impaired cancer cell proliferation was further
explored. STAT-3 vectors were transfected into
MHCC97L cells, and over-expression of STAT-3 obvi-
ously reversed genipin-mediated tumor growth inhib-
ition and STAT-3 target gene suppression (Fig. 3b).
Furthermore, genipin (10 μM) could induce apoptotic
cell death in HCC cells as indicated by western blotting
and Annexin V/7AAD assay (Fig. 3c). Then, whether
genipin inhibited colony formation in MHCC97L and
HepG2 cells was further determined. As shown in Fig.
3d, genipin suppressed colony formation in MHCC97L
and HepG2 cells in a dose-dependent manner. Accumu-
lating evidence suggests that STAT-3 plays a critical role
in angiogenesis under both pathological and physio-
logical conditions, in addition to cell proliferation and
survival [28]. It has been widely recognized that angio-
genesis plays a pivotal role in cancer development, as
malignant tumors need sufficient blood provision if the
tumor is to grow beyond a few cubic millimeters in vol-
ume [29]. One of the most widely applied in vitro exper-
iments to model the reorganization stage of angiogenesis
is the tube construction assay. In our study, genipin
failed to affect HUVEC viability (Supplementary Fig. 4a)
or capillary-like structure construction (Supplementary
Fig. 4b) in the culture medium. However, less well-
formed capillary-like structures were built for HUVECs
in the MHCC97L-conditioned medium after genipin (10
and 20 μM) treatment (Fig. 3e). In conclusion, the above
results revealed that genipin might inhibit HCC prolifer-
ation and angiogenesis.
Genipin suppresses HCC cell invasion and reverses EMT
process
The spread and metastasis of cancer cells may occur by
invading the surrounding tissues and intravasating into
blood or lymphatic circulation through the endothelium
[30]. Herein, cell invasion ability was analyzed by Trans-
well assay using MHCC97L and HepG2 cells. Our re-
sults showed that genipin (10 μM) inhibited HCC cell
invasion dose-dependently (Fig. 4a). Cancer invasion re-
quires an extracellular matrix (ECM) and basement
membrane degradation. Thus, fluorescent-gelatin deg-
radation assay was applied to examine whether genipin
suppresses ECM degradation by HCC cells. Our results
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suggested that MHCC97L cells significantly promoted
ECM degradation in the control group, while genipin
(20 and 50 μM) treatment reversed ECM degradation by
HCC cells (Fig. 4b). 3D culture is an artificially created
environment that provides functional and structural as-
pects of cancer development. In this study, our 3D cul-
ture results showed that genipin (20 and 50 μM)
remarkably suppressed HCC cell invasion via the
Fig. 2 Genipin directly binds with STAT-3-SH2 domain. (a) 3D docking results indicated that genipin could bind to SH2 domain in STAT-3. (b)
Purified GST-tagged STAT-3-SH2 protein was analyzed by SDS-PAGE. Coomassie blue was used to stain the target protein. (c) Fitted curve for
different concentrations of genipin binding to immobilized STAT-3-SH2 by “Affinity” model in the Biocore T300 evaluation software. Differently
colored dots represent different concentrations of genipin. (d) Genipin-suppressed SH2-SH2 interactions. Purified STAT-3-SH2 domain was
incubated with MHCC97L cell lysates after mixing with different dosages of genipin for 1.5 h and analyzed by GST pull-down assay. (e) Genipin
suppressed the dimerization of STAT-3. MHCC97L cells transfected with HA and FLAG-tagged STAT-3 vectors were pre-treated with genipin, the
interaction of FLAG-STAT-3 and HA-STAT-3 were validated by immunoprecipitation assay. (f) Purified STAT-3-SH2 domain was incubated with
MHCC97L cell lysates after mixing with different dosages of genipin for 1.5 h; the interactions of STAT-3-SH2 with EGFR were validated by GST
pull-down. (g) HCC cells (MHCC97L and HepG2) were pre-treated with different dosages of genipin and incubated with EGF; the interactions of
STAT-3 with EGFR were validated by co-immunoprecipitation
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Fig. 3 Genipin inhibits HCC cell proliferation and angiogenesis. (a) MHCC97L, HepG2, or normal haptic cells (LO2) were treated with different
dosages of genipin for 24 h. Cell viability was detected by MTS assay. (b) STAT-3 vector was transfected into MHCC97L cells. Cell viability was
detected by MTS assay, and protein expression of STAT-3 target genes was examined by western blotting. (c) HCC cells were pre-treated with
different concentrations of genipin for 24 h; cell apoptosis was analyzed by flow cytometry using Annexin V/7AAD commercial kit. Expressions of
PARP and cleaved PARP were examined by western blot assay. (d) Colony formation assays were used to detect HCC cell proliferation ability.
MHCC97L and HepG2 cells were incubated with 20-μM genipin for 2 weeks. Results were shown in the histogram from three independent
experiments. (e) Angiogenesis was detected by tube formation assay. 1 × 105 HUVECs were cultured on Matrigel. Cells were incubated with
genipin for 10 h; representative images of tube formation were observed under an inverted microscope (Leica, Germany) and the relative tube
numbers were analyzed. The data presented as mean ± SD. *P < 0.05 and **P < 0.01
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surrounding Matrigel (Fig. 4c). Epithelial-mesenchymal
transition (EMT) is a key process in cancer metastasis by
which epithelial cells lose their polarity and cell-cell ad-
hesion and obtain invasive and migratory properties.
During the EMT process, the expression of several epi-
thelial and mesenchymal biomarkers significantly chan-
ged. Interestingly, genipin treatment notably decreased
the expression of vimentin, fibronectin, and N-cadherin
while increasing the expression of E-cadherin in HCC
cells (Fig. 4d).
Genipin suppresses cancer progression in HCC xenograft
tumor models
To further explore whether genipin suppresses HCC
progression in vivo, orthotopic mice xenograft models
with MHCC97L cells were established. Then, DMSO
Fig. 4 Genipin suppresses HCC cell invasion and reverses EMT process. (a) MHCC97L and HepG2 cells were cultured in trans-well inserts (upper chamber).
Images were obtained via optical microscope after genipin treatment 12 h later; invaded cells were calculated by three individual researchers. Scale bar
50 μm. (b) MHCC97L cells were cultured in FITC-conjugated gelatin (green) for 24 h. Phalloidin was applied to stain F-actin (red) and DAPI used to indicate
nuclei (blue). Black area underneath the cell indicates gelatin degradation area; scale bar 20 μm. (c) To construct the 3D culture system, MHCC97L cells
were seeded into a layer of Matrigel. Then, different dosages of genipin with DMEM and 15% Matrigel were added. Upper mixture was replaced every 24
h. Arrows indicate tubular structure formation on Matrigel. Images were obtained via optical microscope after genipin treatment 96 h later; scale bar
50 μm. (d) Protein expressions of vimentin, fibronectin, N-cadherin, and E-cadherin were validated by western blot and immunofluorescence staining
(green). Nuclei were stained by DAPI (blue). Scale bar 20 μm. Data presented as mean ± SD. *P< 0.05, **P< 0.01, and ***P< 0.001
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(0.1%) (vehicle) or genipin was administrated daily by in-
traperitoneal injection. Figure 5a shows that genipin
treatment (25 and 50 mg/kg) notably decreased tumor
weight, which indicated that genipin could inhibit HCC
progression in vivo. In addition, genipin treatment also
significantly decreased the number of metastasis nodules
in the lungs (Figs. 5b and c). Further studies demon-
strated that genipin suppressed the protein expression of
phospho-STAT-3 (Y705) and inhibited the expressions
of STAT-3 target genes in primary liver tumor tissues
(Figs. 5d and e). Furthermore, decreased vascular density
was detected by CD31 staining in HCC tissues in
genipin-treated mice (Fig. 5e). The survival rate of mice
was analyzed to evaluate whether the metastasis inhib-
ition effects of genipin could improve the overall survival
rate. Our results showed that genipin significantly
Fig. 5 Genipin suppresses HCC progression and improves survival rate of tumor-bearing mice. MHCC97L cells (5 × 105) were used to established
orthotopic mice xenograft models. Tumor-bearing mice were administrated with DSMO or genipin by intraperitoneal injection (n = 8). (a) Tumor
weight of primary liver cancer in mice was detected after DSMO (0.1%) or genipin treatment. (b) To evaluate lung metastasis in orthotopic
transplantation HCC mice, lung tissues were dissected after DSMO or genipin treatment. Representative paraffin sections of lung tissue were
stained with hematoxylin and eosin at 20× magnification. Scale bar 100 μm. (c) Lung metastasis was examined under anatomic microscope and
number of metastasis nodules was calculated by three individual researchers. (d) Protein expression of p-STAT-3 (Y705) and target gene
expression in primary liver tumors were detected by western blot assay. (e) Protein expressions of CD31 and phospho-STAT-3 were evaluated by
immunohistochemical method. Scale bar 40 μm. (f) Overall survival was analyzed after DSMO or genipin treatment (0–50 d) in tumor-bearing
mice. Genipin vs vehicle (25 mg/kg), P = 0.0002; genipin vs vehicle (50 mg/kg), P < 0.0001. Data presented as mean ± SD. **P < 0.01
and ***P < 0.001
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improved the survival rate of tumor-bearing mice. No
mice in the vehicle group (n = 8) survived by day 40,
whereas six mice survived by days 40 and 50 after geni-
pin (50 mg/kg) treatment (Fig. 5f). In conclusion, the
above results suggested that genipin could inhibit HCC
metastasis and improve the overall survival rate in
orthotopic transplantation HCC mice models.
Anti-HCC effect of genipin in patient-derived HCC
xenograft mice model
A patient-derived xenograft (PDX) mice model may retain
more similarities to human cancers compared to a normal
cell-line xenograft mice model. Previous studies have
shown that PDX mice models may be useful for screening
novel anti-cancer agents [31]. Herein, seven human surgi-
cal HCC tissue samples along with the peripheral normal
liver tissues were collected from primary HCC patients
(Supplementary Table 1). First, the protein expressions of
STAT-3 and p-STAT-3 (Y705) in these surgical samples
were detected. Our results indicated that the expressions
of STAT-3 and p-STAT-3 (Y705) were notably reduced in
HCC peripheral normal liver tissues compared to tumor
tissues (Fig. 6a). These results suggested that the activation
of STAT-3 is up-regulated in tumor cells derived from
HCC patients. After establishing the PDX mice model, the
protein expressions of STAT-3 and p-STAT-3 (Y705) in
tumor-bearing mice were examined. No obvious changes
were found in the expression of p-STAT-3 (Y705) in F0,
F1, F2, and F3 passages (Fig. 6b). The above results indi-
cated that the activity of STAT-3 was not changed in
patient-derived HCC xenograft mice after serial passages
culture. The F3 passages mice were divided into DMSO
(0.1%) and genipin (25, 50mg/kg/d) treatment groups
(n = 8). After genipin treatment, the HCC growth in mice
was significantly suppressed (Fig. 6c). The tumor volume
in the genipin treatment (25 and 50mg/kg/d) group was
597.43 and 401.26mm3, respectively. In contrast, the
tumor volume in the vehicle treatment group was
1452.24mm3 (Fig. 6d). In addition, the tumor weight in
the liver remarkably decreased after genipin (25 and 50
mg/kg/d) treatment (Fig. 6e). Interestingly, genipin also
decreased the protein levels of p-STAT-3 (Y705) and
STAT-3 target genes (Bcl-2, VEGF, and Survivin) in the
mice model (Fig. 6f). Immunohistochemistry assay further
confirmed the decreased expression of p-STAT-3 (Y705)
as well as the tumor vascular density (CD 31+) in HCC
samples from PDX mice after administration with genipin
(25 and 50mg/kg/d) (Fig. 6g).
Genipin inhibits proliferation of other cancer cells
Considering that STAT-3 signaling regulates oncogenic
pathways in various tumor cells, it was hypothesized that
genipin might also inhibit the growth of other cancer
cells. Figure 7a shows that genipin (20 and 50 μM)
exposure resulted in the growth inhibition of various
kinds of cancer cells. In addition, genipin notably sup-
pressed the STAT-3 signal pathway in these tumor cells.
Figure 7b shows that the activation of p-STAT-3(Y705)
was significantly inhibited by genipin treatment in vari-
ous non-HCC cancers.
Potential toxicity of genipin on tumor-bearing mice
To evaluate the potential toxicity of genipin in vivo, the
effects of genipin on kidney and liver functions in
tumor-bearing mice were further examined. No obvious
changes in serum creatinine, blood urea nitrogen, aspar-
tate transaminase (AST), and alanine transaminase
(ALT) levels between genipin and DMSO group were
detected (p > 0.05) (Supplementary Table 2). In addition,
body-weight changes in mice were detected every 7 d.
No significant loss of body weight was detected after
genipin treatment (Supplementary Fig. 5a). Furthermore,
H&E staining results indicated no obvious histological
changes between genipin-treated mice and control mice
(Supplementary Fig. 5b). In conclusion, these data sug-
gested that genipin exhibits no significant adverse effects
on mice at the therapeutic dosage.
Discussion
Discovering novel agents from natural products for
HCC treatment may provide promising therapeutic
drugs for improving patient survival [32, 33]. In the
current study, it was found that a small natural com-
pound, genipin, could inhibit STAT-3 activity in vitro
and in vivo. Our molecular docking study indicated that
genipin could bind to the SH2-STAT-3 domain, which
was further confirmed by in vitro studies. For the first
time, to the best of our knowledge, it was demonstrated
that genipin could inhibit HCC progression by targeting
the STAT-3 signal pathway (Fig. 8).
Previous studies have shown that genipin could induce
apoptosis in HCC cells, detected by caspase activation,
cytochrome C release, and changes in cellular morph-
ology [34]. Further studies indicated that genipin-
mediated HCC apoptosis might induce by NADPH
oxidase-dependent generation of ROS, which resulted in
JNK activation. Another study by Wang et al. showed
that genipin might inhibit the intrahepatic metastasis
with few adverse effects, and p38/TIMP-1/MMP-2 sig-
naling may be involved as the key mechanism of geni-
pin’s anti-metastasis effects [35]. Another recent study
found that 50-mM genipin decreased the migratory dis-
tance by 43 and 72% in HCC cell lines. Genipin might
down-regulate matrix metalloproteinases genes and pro-
tein expressions; decrease the expression of nuclear fac-
tor kappa-light-chain-enhancer of activated B cells,
phosphorylated protein kinase B, urokinase-type plas-
minogen activator, phosphorylated mitogen-activated
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protein kinase, and activator protein 1; and up-regulate
tissue inhibitor metalloproteinases genes as well as the
protein expression in HCC [36]. Aside from its potential
anti-HCC effects, genipin also showed therapeutic po-
tential in hepatitis, hepatic injury, non-alcoholic fatty
liver disease, and other non-cancer hepatic diseases,
which might prevent the tumorigenesis of HCC [37]. Al-
though genipin has shown inhibitory potency in HCC
cells, its effects on STAT-3 activity in HCC has not been
reported yet. Herein, for the first time, the anti-HCC ef-
fects of genipin and the involvement of STAT-3 in these
effects were explored.
Fig. 6 Genipin exhibits anti-HCC effects in PDX mice model. (a) Protein expression of STAT-3 and p-STAT-3 (Y705) in human HCC tissue and para-
carcinoma tissue were examined by western blot assay. (b) Graphical representation of constructing PDX mice model. Protein expression of STAT-
3 and p-STAT-3 (Y705) were detected in F1, F2, and F3 generation. (c) Tumor sizes were measured after genipin treatment in PDX model (n = 8).
(d) Tumor volume in PDX mice was examined after genipin treatment (n = 8). (e) Tumor weight in PDX mice was examined after genipin
treatment (n = 8). (f) Expression of p-STAT-3, STAT-3, Survivin, Bcl-2, and VEGF was examined by western blotting in HCC tissues. (g) Expression of
CD31 and p-STAT-3 was validated by immunohistochemistry assay in HCC tissues. Scale bar 40 μm. Data presented as mean ± SD. **P < 0.01
and ***P < 0.001
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Fig. 7 Genipin suppresses proliferation of various non-HCC cancer cells. (a) Colon, gastric, ovarian, breast, prostate, cervix, and pancreas cancer
cells were pretreated with genipin (20 and 50 μM). Living cells were detected by MTS assay after 36 h of incubation. (b) Various non-HCC cancer
cells were pre-treated with genipin (20 and 50 μM) for 12 h. Expressions of p-STAT-3 and total STAT-3 were examined by western blot assay. Data
presented as mean ± SD. **P < 0.01 and ***P < 0.001
Fig. 8 Graphic illustration of signaling underlying molecular mechanism of anti-HCC effects of genipin
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The SH2 domain is a structurally conserved protein
domain contained within the STAT-3 protein. SH2 do-
mains can promote STAT-3 dimerization by docking to
phosphorylated tyrosine residues on STAT-3 [38]. This
dimerization changes the STAT-3 conformation and fa-
cilitates target DNA recognition as well as regulation of
gene expression. Our in silico studies suggested that
genipin could bind to the SH2-STAT-3 domain, which
was further confirmed by SPR study. In addition, co-
immunoprecipitation assay indicated that genipin inhib-
ited STAT-1:STAT-3 heterodimerization and STAT-3:
STAT-3 homodimerization. In previous research, Maha-
lapbutr et al. found that the SH2 domain was critical for
EGFR and STAT-3 interaction and subsequent STAT-3:
STAT-3 homodimerization [39]. In our study, it was re-
vealed that genipin could suppress EGFR-STAT-3 inter-
action and further inhibit STAT-3 dimerization. The
STAT-3 protein has two critical phosphorylation sites,
Ser727 and Tyr705, for its activation. However, genipin
failed to phosphorylate STAT-3 on the Ser727 site in
this study. Thus, it is speculated that genipin can inhibit
STAT-3 activity by suppressing STAT-3 phosphoryl-
ation on the Tyr-705 site.
In this study, genipin suppressed HCC cell prolifera-
tion by regulating the expression of survivin, Mcl-1, and
Bcl-2 genes. However, genipin failed to affect several
common signal pathways that have a close association
with cancer proliferation, e.g., the mTOR, STAT-5,
STAT-1, STAT-2, and MAPK pathways. Thus, it is spec-
ulated that genipin might inhibit HCC cell proliferation
by specifically suppressing STAT-3 activity. Ulaganathan
et al. revealed that STAT-3 was constitutively activated
in malignancy instead of normal tissues [40, 41]. Inter-
estingly, our results showed that genipin selectively sup-
pressed HCC cell proliferation without significant
toxicity in normal cells. These findings suggested that
STAT-3 might be a promising therapeutic target for
cancer treatment with few side effects. The vascular
endothelial growth factor (VEGF), originally known as
the vascular permeability factor (VPF), is a signal protein
that can stimulate the formation of blood vessels in can-
cer development [42]. Sim et al. showed that STAT-3
could regulate the expression of VEGF in various types
of cancers [43]. Herein, our results demonstrated that
genipin remarkably decreased the expression of VEGF in
HCC cells. Chromatin immunoprecipitation results con-
firmed that STAT-3 could regulate the expression of
VEGF and inhibit STAT-3 binding to the promoter re-
gion of VEGF. In addition, HUVEC tube construction
assay showed that less well-formed capillary-like struc-
tures were built for HUVECs in the tumor-conditioned
medium derived from genipin-treated cells. In vivo stud-
ies further confirmed the decreased cancer vascular
density in mice after genipin treatment by IHC assay. In
conclusion, the decreased expression of VEGF regulated
by STAT-3 might contribute to genipin-induced cancer
angiogenesis suppression. One insufficiency of the
present study is that Akt pathway in genipin-induced
HCC proliferation inhibition was not investigated. Previ-
ous studies showed that regulation in the Akt pathway
could affect growth factors, receptor tyrosine kinases,
Ras, and the PI3K p110 sub-unit, resulting in abnormal
cancer cell proliferation [30, 44]. Therefore, in future
studies, further exploration of the potential role of the
Akt pathway in genipin-induced HCC suppression is
planned.
Cancer metastasis is a pathological process in which
malignant cells spread from a primary site to a different
site within the host’s body [45, 46]. The degradation of
ECM plays a pivotal role in the process of metastasis.
MMP-2, a type IV collagenase, can facilitate ECM deg-
radation and promote cancer metastasis. Previous stud-
ies showed that STAT-3 could regulate the expression of
MMP-2 in cancer cells [47]. In our study, genipin not-
ably suppressed the expression of MMP-2 in HCC cells
and inhibited the degradation of ECM. The epithelial-
mesenchymal transition (EMT) is a process by which
epithelial cells lose polarity and adhesion ability, which
can promote cancer cell metastasis [48]. Xiong et al.
found that STAT-3 might directly induce EMT progres-
sion and modulate ZEB1 expression in colon cancer
cells. Knockdown of STAT-3 can up-regulate the ex-
pressions of E-cadherin and down-regulate N-cadherin
and vimentin in colon cancer [1]. According to our re-
sults, genipin can also regulate EMT-relevant protein ex-
pression in HCC. Furthermore, genipin treatment
remarkably suppressed HCC lung metastasis in a xeno-
graft mice model. The above results suggested that geni-
pin might inhibit MMP-2 expression and block the
process of EMT in HCC by targeting STAT-3 activity,
which could suppress HCC metastasis.
A patient-derived xenograft (PDX) mice model refers
to the transferring of human cancer samples to immu-
nodeficient mice after surgical operation. As PDX can be
passaged without in vitro processing procedures, a PDX
model enables the propagation and expansion of human
cancers without oblivious genetic transformation of can-
cer cells over multiple murine generations [49]. Within a
PDX model, human cancer can grow in a physiologically
relevant cancer microenvironment that mimics the hor-
mone, nutrient, and oxygen levels that are observed in
primary human cancer tissues [50]. Thus, a PDX model
shows significant advantages over established cancer cell
lines in cancer research. Herein, it was found that geni-
pin exhibits notable therapeutic effects in an HCC PDX
mice model. Our in vivo results indicated that the ex-
pression level of p-STAT-3 (Y705) was higher in cancer
tissues than para-carcinoma tissues. Furthermore, HCC
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PDX mice still exhibit a high expression of p-STAT-3
(Y705) after continuous passage.
In conclusion, genipin showed therapeutic potential
for HCC treatment by directly interacting with the SH2-
STAT-3 domain, which suppressed the activity of
STAT-3. Our study may form the baseline research for
future clinical trials and suggests genipin as a novel in-
hibitor of STAT-3. In addition, more in-depth research
could be conducted to explore the potential role of geni-
pin in combination with chemotherapy for HCC in fu-
ture studies.
Conclusions
In conclusion, in this study, genipin showed therapeutic
potential for HCC treatment by interacting with the
SH2-STAT-3 domain and suppressing the activity of
STAT-3. In the future, further research is planned to ex-
plore the potential role of genipin in combination with
chemotherapy or radiotherapy for HCC treatment.
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Additional file 1: Supplementary Figure 1. Genipin failed to affect
the expression of PTPases or activation of STAT-1, STAT-2, STAT-5, mTOR
and MAPK signal pathways. (a) For validating the effects of genipin on
the expression of PTPases , western blot assay was applied after genipin
treatment.(b) For validating the effects of genipin on the activation of
STAT-5, STAT-2, STAT-1, western blot assay was applied after genipin
treatment. (c) For validating the effects of genipin on the activation of
MAPK and mTOR signaling pathways, western blot assay was applied
after genipin treatment. Supplementary Figure 2. Genipin inhibits the
formation of STAT3-STAT1 heterodimer. (a) MHCC97L cells were trans-
fected with HA-tagged STAT1 and FLAG-tagged STAT3 and pretreated
with genipin, the binding ability of STAT3-STAT1 was validated by west-
ern blotting and immunoprecipitation assays. Supplementary Figure 3.
Genipin suppresses the protein expression of p-STAT3 (Y705) in HCC cells.
(a) HCC and normal liver cells were treated with genipin for 12 h, cells ex-
tracts were prepared and protein expressions were examined by western
blot assay. Supplementary Figure 4. Genipin failed to affect the prolif-
eration of HUVECs and capillary structure formation. (a) HUVECs were
treated with genipin (5,10, 20, 50 μM ) for 24 h and examined by MTS
assay. (b) 5×103 HUVECs were cultured in 24-well plates, then, genipin
(10, 20, 50 μM ) were exposed to cells.. After 12 h incubation, Tubular
structures were observed by inverted microscope(Carl Zeiss Vision, Ger-
meny) and analyzed by Pro-Image ( Media Cybernetics, USA) software.
The data represents mean ± SD. Scale bar = 20 μm. Supplementary
Figure 5. The potential cytotoxicity of genipin in vivo. (a) Nude mice
were administrated with genipin (50 mg/kg/day) or DMSO by i.p. injec-
tion for 4 weeks (n = 6). The body weight was detected each week. (b)
H&E staining results of brain, heart, lung, kidney and spleen organs from
DMSO group and genipin group. Scale bar=20 μm. Supplementary
Table 1. The information of HCC patients with tumor resection operation
Supplementary Table 2. The effects of genipin on kidney and liver
functions in nude mice Supplementary Table 3. The primer sequences
used in RT-PCR assay
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